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Chronic pain is a global problem affecting up to 20% of the world’s population and has a 
significant economic, social and personal cost to society. Sensory neurons of the Dorsal Root 
Ganglia (DRG) detect noxious stimuli and transmit this sensory information to regions of the 
central nervous system (CNS) where activity is perceived as pain. DRG neurons express 
multiple voltage-gated sodium channels that underlie their excitability. Research over the last 
twenty years has provided valuable insights into the critical roles that two channels, NaV1.7 
and NaV1.9, play in pain signalling in man. Gain of function mutations in NaV1.7 cause painful 
conditions while loss of function mutations cause complete insensitivity to pain. Only gain of 
function mutations have been reported for NaV1.9. However, while most NaV1.9 mutations lead 
to painful conditions a few are reported to cause insensitivity to pain. The critical roles these 
channels play in pain along with their low expression in the CNS and heart muscle suggest 
they are valid targets for novel analgesic drugs.  
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Pain is an important warning system to guard against tissue damage and disease. Pathological pain, 
however, has no warning value and has huge economic, social and personal costs to society. Chronic 
pain is a global problem affecting up to 20% of the world’s population [50,9]. Sensory neurons of the 
Dorsal Root Ganglia (DRG) detect painful stimuli and transmit sensory information to regions of the 
central nervous system (CNS) that perceive pain. DRG neurons are a heterogeneous population of 
neurons with distinct functional and histochemical properties [77,53]. The DRG contain neurons 
responding to a variety of non-noxious stimuli (such as proprioceptors and low-threshold 
mechanoreceptors) as well as those responding to noxious stimuli (nociceptors).  
Inflammation and nerve injury sensitise DRG neurons and result in decreased pain thresholds and/or 
intense pain. This can be in part due to increased voltage-gated sodium channels (VGSC) activity 
resulting in increased excitability of DRG neurons [8,103]. VGSCs consist of pore forming α-subunits 
and auxiliary β-subunits. There are ten cloned α-subunits and 4 β-subunits. The β-subunits modulate 
the localisation, expression and functional properties of α-subunits [12]. Each -subunit is composed 
of four homologous membrane-spanning domains (DI-DIV). Each domain consists of six 
transmembrane segments (S1-S6) [12]. Different α-subunits have distinct electrophysiological and 
pharmacological properties [12,103], and DRG neurons express multiple α-subunits that are essential 
to their ability to fire action potentials [103]. 
This review aims to clarify the roles of two VGSC channels expressed selectively, though not 
exclusively, in primary sensory neurons, in pain pathways, and in light of evidence from genetic 
mouse model and mutations in man. We discuss the usefulness of these channels as potential drug 
targets, and suggest that while our present understanding of function has grown more complex, 
targeting these channels either alone or in combination may still provide a strategy for analgesic 
development, potentially even for chronic use. 
VGSC as targets for analgesic drugs  
There are two reasons why VGSCs are attractive targets for analgesic drugs. Firstly, VGSC are 
required for the firing of action potentials in DRG neurons, therefore, blocking their activity will reduce 
pain signalling in painful conditions even if they were not the primary or only contributor to increased 
firing. For example, sensitisation of primary transducing channels, like the transient receptor potential 
(TRP) channels, is often involved in many forms of pathological pain [11,90,105]. This sensitisation 
will lead to greater generator potentials in sensory nerve terminals. However, since VGSC are 
required to initiate an action potential in nerve terminals and to allow conduction into the CNS, an 
effective VGSC blocker can still cancel out the effect of the sensitised TRP channels in nerve 
terminals.  
Secondly, a few of the VGSC  subunits expressed in DRG are either exclusive to, or enriched in 
DRG neurons that signal pain, with little expression in other DRG neurons, the CNS, skeletal and 
heart muscles. Blockers for these subunits would therefore be expected to produce analgesia without 
detrimental side effects. DRG neurons express many of the cloned  subunits [103], however, three 
subunits (Nav1.7, Nav1.8 and Nav1.9) meet the above criteria. Not surprisingly, many pharmaceutical 
companies are developing and testing subunit specific Nav1.7, NaV1.8 and NaV1.9 blockers as 
analgesics [128,38].  
The three -subunits differ in their biophysical properties that determine their role in neuronal 
excitability [103]. The NaV1.9 channel activates over a negative range of membrane potentials close 
to the resting potential and generates a persistent current. Evidence suggests that it is powerfully 
regulated by g-protein pathways, in a unique way. Therefore, when it is activated, it contributes to 
setting the resting membrane potentials of neurons expressing it [22]. Nav1.7, generates a transient 
Na+ current, but has a relatively slower rate of inactivation near the resting potential (slow closed-state 
inactivation) allowing the channel to generate persistent currents and making it a so-called ‘threshold 
channel ‘[24,25]. Nav1.8 has a relatively depolarised activation voltage (~ -20mV) compared to Nav1.7 
and Nav1.9 [2,103], thus Nav1.8 activation comes after and perhaps subsequent to the activation of 
Nav1.9 and Nav1.7 channels. Nonetheless, Nav1.8’s depolarised inactivation and more rapid recovery 
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from inactivation allows it to contribute to repetitive firing, for example [103]. This review will focus on 
NaV1.9 and Nav1.7 subunits since their biophysical properties allow them both to influence pain 
thresholds through setting the membrane potential and action potential threshold in DRG neurons. 
Role of Nav1.7 in pain 
Nav1.7 was cloned from PC12 cells in 1997 [118]. At that time NaV1.8 and NaV1.3 channels were 
already under the spot-light and their role in pain was actively being investigated. NaV1.8 was cloned 
in 1996 and its strong expression in medium and small sensory neurons (the sizes of most 
nociceptors) made it the best and most obvious target for analgesic drug development [2]. The NaV1.8 
knockout mouse was reported three years later and although it showed a pain deficient its phenotype 
was compromised by a compensatory upregulation of Nav1.7 [3] with clear functional consequences 
[3,89]. However, knock-down of Nav1.8 by antisense oligo nucleotides in adult rats inhibited 
neuropathic pain [75,129]. The difference could be due to the timing of the deletion (embryonic versus 
adult) or the animal model used (mouse versus rat).  In contrast to Nav1.8, the expression pattern of 
Nav1.3 does not suggest it would be a useful drug target. Nav1.3 is expressed throughout the nervous 
system and its expression is highest during embryonic development and decreases postnatally [122].  
However, Nav1.3  is the only channel that is re-expressed in DRG following nerve injury and diabetes 
[121]. This made it a potentially viable target for analgesics. However, mice lacking Nav1.3 do not 
show any deficits in pain phenotype [91]. 
Nav1.7 became the focus of the pain field in 2004 with the publication of two papers [127,92]. The first 
paper identified a mutation in SCN9A (the gene coding for Nav1.7) as the cause for a rare inherited 
pain condition known as Primary Erthromelalgia (PEM). PEM symptoms starts at early age with 
episodes of pain in the extremities (usually in the feet) that are triggered by exposure to heat or 
walking [127]. The second paper reported the complete absence of inflammatory pain in a conditional 
mouse lacking Nav1.7 in most nociceptors [92]. The conditional ablation in nociceptors was achieved 
using a Cre driver mouse line where Cre is expressed by the Nav1.8 promotor [113]. The complete 
loss of all inflammatory pain and mechanical pressure after ablation of Nav1.7 in nociceptors [92] 
excited the pain field and stimulated drug discovery programmes at several pharmaceutical 
companies [38,128]. A conditional mouse was generated because global deletion of Nav1.7 in mouse 
proved to be lethal [92]. Global knockout pups were born alive but failed to feed and died within 24 
hours. Hand feeding and special husbandry arrangements allow Nav1.7 global KO to survive to 
adulthood [49]. Inducing Nav1.7 ablation in adult mice causes pain deficits without detrimental effects 
[107].  
Remarkably, the symptoms of PEM patients complemented the phenotype of the conditional Nav1.7 
null mice. While pain can be triggered by mechanical pressure on feet (walking and exercise) 
conditional null mutants showed a complete loss of pain to mechanical pressure. While PEM patients 
showed signs of inflammatory pain (heat, redness and occasionally swelling of feet), conditional null 
showed a complete loss of inflammatory pain. This helped support the hypothesis that blocking 
Nav1.7 in humans would significantly reduce pain signalling. However, the mouse study raised 
significant questions. Firstly, is the role of Nav1.7 in pain signalling in humans as critical as it is in 
mice, in other words, would the loss or block of Nav1.7 in humans lead to the all or none loss of pain 
seen in mice? Furthermore, if this is the case, then would the loss or block of Nav1.7 in humans result 
in lethality (as it did in mice)?  These questions were critical for the validity of Nav1.7 as a drug target. 
These questions were answered in 2006 when it was reported that a loss of function mutation in 
SCN9A causes complete insensitivity to pain (CIP) [19]. In CIP patients, perception of non-noxious 
touch and warmth is not affected whereas perception of noxious heat, pressure and injury pain is 
completely lost. CIP patients confirmed that Nav1.7 plays as critical a role in pain signalling in humans 
as it does in mice. Importantly, loss of Nav1.7 did not lead to lethality nor any significant disability (CIP 
patients are anosmic due to the expression of Nav1.7 in olfactory epithelia [135]). A second heritable 
painful condition was mapped to a gain of function mutation in SCN9A in the same year (2006). 
Perixsomal extreme Pain disorder (PEPD, initially known as familial rectal pain) was found to be 
caused by a gain of faction mutation in the Nav1.7 channel [45]. The four papers between 2004 and 
2006 provided very strong evidence that Nav1.7 is a critical player in pain signalling, catapulting it to 
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the top of the list of analgesic drug targets. Since then, human geneticists have identified scores of 
mutations causing PEM, PEPD, CIP and Small Fibre Neuropathy (SFN).  
Primary Erythromelalgia (PEM) 
Primary erythromalgia is an autosomal dominant condition caused by a mutation in the SCN9A gene. 
The condition was first mapped to SCN9A in 2004 by Yang et al [127]. The proband suffered from 
bilateral episodes of burning pain in their hands and feet that started during their childhood and 
continued throughout their life. During the attacks the feet and hands became warm and red. The pain 
episodes were triggered by exercise or exposure to heat. The proband had the nonsense mutation 
L858H which is located in the second domain, figure 1. Characterisation of the channel’s biophysical 
properties showed that the mutation shifted the activation voltage about 12 mV in the hyperpolarising 
direction resulting in a reduced threshold for channel opening and thus increased excitability [23]. 
Since the first report, several mutations have been reported that cause PEM, listed in Table 1 in 
chronological order.  Symptoms appears early in life although late onset cases have been reported 
[17,21]. All PEM mutations cause similar changes to the biophysical properties of Nav1.7, involving a 
shift of the activation voltage to hyperpolarised potentials [30], and where the magnitude of the shift 
seems to affect the severity of the symptoms [55]. Furthermore, PEM mutations tend to cluster in 
domains I and II of the channel protein, figure 1.  
Treatment for PEM patients includes avoidance of the conditions that trigger pain (i.e. heat and 
physical pressure on feet). Patients typically resort to foot lifting, cooling feet by fans or immersing 
them in water or iced water to reduce or relief pain. Although immersion in cold water is effective for 
mild cases, it can result in ulceration and maceration of foot skin leading to infection [116,19]. 
Recently, it has been reported that behavioural therapy reduced dependence on water immersion in 
PEM patients [67]. There is no consensus on pharmacotherapy. Among effective drugs are non-
selective sodium blockers (lignocaine, mexiletine and carbamazepine)[116,82] which have been 
shown to inhibit Nav1.7[133,120] . 
Paroxysmal extreme pain disorder (PEPD) 
Paroxysmal extreme pain disorder (PEPD, formerly known as Familial Rectal Pain Syndrome) is 
caused by gain of function mutations in SCN9A that alter the biophysical properties of the Nav1.7 
channel [45]. There are several similarities between PEPD and PEM. Both are autosomal dominant 
conditions with symptoms starting early in childhood (PEPD is observed in infants [16]). PEPD is 
characterised by episodes of severe burning pain in the rectal, ocular, and mandibular areas 
accompanied by flushing of the skin. Pain in PEPD patients is triggered by otherwise innocuous 
mechanical stimulation (defecating, chewing and yawning) and warmth of the affected areas. 
However, functional characterisation of mutant Nav1.7 channels showed that they have normal 
activation voltages (unlike PEM mutations). In contrast, PEPD mutations cause a depolarising shift in 
inactivation voltages with incomplete channel inactivation, leading to a persistent current and 
increased excitability [7,119,45]. 
Table 2 lists reported SCN9A mutations that are found in PEPD patients. PEPD mutations tend to 
cluster in domain III and IV of the channel protein, figure 2. Despite the severity of the pain, PEPD 
patients responded well to the anti-epileptic drug carbamazepine [117].  
Heritable Small Fibre Neuropathy (SFN) 
Small fibre Neuropathy is caused by damage to thinly myelinated and unmyelinated nerve fibres. SFN 
is often characterised by late onset, bilateral burning pain to hands and feet. SFN is also associated 
with disturbances to autonomic functions like sweating, dryness in eyes or mouth, disturbance to 
bowel and bladder functions [117]. Autonomic symptoms are not reported in both PEM and PEPD. 
Diagnosis is usually confirmed by a decrease in intra-epidermal fibre density (IDFD) in skin biopsies. 
Several conditions can cause SFN, these include diabetes and autoimmune disease [112,52]. About 
50% of SFN cases are idiopathic, with no obvious aetiology [112]. The dominant pattern of inheritance 
of SFN in some cases of idiopathic SFN suggested mutations in a single gene [112,52]. Mutations in 
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the three peripheral VGSCs, Nav1.7 [10], Nav1.8 [44] and Nav1.9 [64] channels have been found in 
heritable SFN cases.  
Characterisation of Nav1.7 channels in SFN patients, listed in table 3, showed that they would cause 
hyperexcitability [62,43], however, it is not clear how this leads to a small fibre neuropathy and why it 
is of late onset. Nav1.7 channel mutations linked to SFN are not localised to a particular region within 
the channel but many are clustered in the first intracellular loop between domains I and II, figure 3. 
Recently a clinical trial has found lacosamide to be efficacious in reducing pain and wellbeing of SFN 
patients with SCN9A mutations [27], however, the effect was linked to subset of SCN9A mutations 
[74]. 
 
Role of Nav1.7 in epilepsies 
Although the expression of Nav1.7 in the human brain is poorly characterised, there is emerging 
evidence that Nav1.7 plays some role in modulating excitability in the brain. It is known that CIP 
patients suffer from the loss of the sense of smell due to expression of Nav1.7 in olfactory epithelia 
[135] and a patient with the PEM mutation N1245S displayed high olfactory sensitivity [54]. However, 
CIP patients are not reported to suffer from brain related symptoms. Nonetheless, several papers 
have recently reported mutations in SCN9A in patients with various types of epilepsies, table 4. These 
mutations are mostly localised to the DI-DII part of the channel, figure 4. The above suggests that 
while a loss of Nav1.7 function has no detrimental effect on the brain, altered or increased Nav1.7 
function does. Therefore, further research is needed to provide insights onto the type of cells that 
express Nav1.7 (types of neurons? any in glia?) in brain. Furthermore, knock-in models will help to 
explore how the mutations cause epilepsy rather than act as modifiers to changes in other genes (e.g. 
SCN1A, SCN2A and SCN3A). Finally, it is intriguing that a few mutations (e.g. Q10R) cause PEM in 
some patients, and epilepsy in others. This may suggest that variations in the functional expression of 
other genes or epigenetic changes influence the biological consequences of mutations in Nav1.7.      
Complete insensitivity to pain (CIP) 
Complete insensitivity to pain is characterised by loss of all pain sensations throughout patient’s life.   
SCN9A loss of function mutations cause an autosomal recessive CIP [19,34]. Several mutations have 
been identified, most are non-sense mutations causing truncated proteins, table 5. Most of the 
mutations are located within domains I and II, figure 5. There is recent evidence that the CIP 
phenotype involves changes to endogenous opioids [87,97], however, this was not observed in a rat 
null model [14].  
Role of Nav1.9 in pain 
Nav1.9 –(gene name SCN11A), is a tetrodotoxin-resistant (TTX-r), so called persistent Na+ current, 
with clear evidence for functional expression in nociceptive primary sensory neurons in the dorsal root 
ganglia (DRG) and trigeminal (e.g. [22,6]), and the AH cells of the myenteric plexus in the gut 
[102,18]. The human clone (first named as SCN12A, 73% identical with rat SCN11A, [68]; had initial 
reported expression in the placenta, spleen, small intestine, spinal cord and brain (potentially neurons 
and glia)). In primary sensory neurons it has been associated with nerve endings in tooth-pulp and 
cornea using immunohistochemical methods, and evidence suggests it is found distributed along IB4+ 
axons in the sciatic nerve (e.g. [47,28,95]), furthermore, the channels have been located to gut 
afferents [60,61] and also to the bladder [101] using electrophysiological methods in gene knock-out 
mice 
The functional properties of the channel currents were first identified in Nav1.8 knockout mouse 
sensory neurons, because under these circumstances the channel generates the only tetrodotoxin-
resistant (TTX-r) Na+ current [22,84]. The channel produces a Na+ current in sensory neuron cell 
bodies that has ultra-slow activation and inactivation kinetics. It gives rise to a persistent, non-
inactivating current operating over the negative portion of its activation membrane potential range, 
allowing it to act as a ‘threshold channel’, and to contribute to setting the membrane potential. Its 
unusual kinetic properties, and negative activation range produce ‘plateau potentials’ that amplify 
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applied or transduced sub-threshold depolarizations and massively prolong them in duration (figure 
6). It is worth noting that Nav1.9 has activation kinetics that are too slow to directly contribute to 
impulse firing. 
 
Intracellular dialysis of the non-hydrolysable GTP analogue, GTP--S, up-regulated the Nav1.9 current 
with no changes in current kinetics, recorded in voltage-clamp. It was also found that at a membrane 
potential of near -60 mV, functional upregulation of the current can cause sensory neurons to fire 
rhythmically and spontaneously, at low frequency, (figure 6) [6]. The current could be upregulated 
following the activation of ATP receptors, deduced to be P2Y, operating through a probable Gq/11 
pathway and PKC [6,5], such a pathway has later been confirmed to be a contributor to modifying the 
firing properties of gut afferents. 
There are several mouse knockouts of SCN11A reported in the literature and these have been 
associated with an elimination of the GTP--S upregulated current in primary sensory neurons [94] 
and a complementary reduction in forms of inflammatory pain following exposure to PGE2 [4] and 
including the formalin and CFA tests [99] – consistent with a role of Nav1.9 in inflammatory pain in 
both the skin and gut.  A likely role for Nav1.9 in the control of normal gut motility, attributable to 
altered plexus function, seems consistent with the effects of mutation in human carriers and gain of 
function is associated with constipation (e.g. [69]). With these facts in mind, it may be possible to 
understand the defects in pain signalling found in humans with rare, heritable mutations in SCN11A.  
Painful and painless Nav1.9 Channelopathies  
About 20 mutations have been reported for SCN11A, table 6. All follow a dominant inheritance 
pattern. Most mutations have been confirmed to lead to a gain of function. No loss of function 
mutations have been reported to date which could be because such mutations cause mild or no effect 
on pain signalling in humans (given the phenotype of knockout mice it is very unlikely that human loss 
of function mutation causes lethality). It is also possible that the loss or reduction of inflammatory pain 
may mean such individuals are unlikely to have a reason to visit the doctor! 
The persistent nature of Nav1.9 currents, and the negative activation voltage-dependence makes the 
channel functionally unique. It is proposed to act as a threshold channel in peripheral nociceptors, so 
gain of function mutations associated with facilitated activation would be expected to give rise to 
painful neuropathy, because the threshold for action potential generation is reduced. Indeed, SCN11A 
mutations result in two painful conditions, familial episodic pain [131,79,93,63] and painful small fibre 
neuropathy [64,57,48]. In familial episodic pain, painful episodes centre on regions on the arms and 
legs, in addition, there are age-related decreases of pain, suggesting real age-related changes in 
gene expression. Painful episodes (lasting 10s of minutes) are associated with rainy days, cold 
temperature and commonly also fatigue; some are associated with gut motility symptoms. Further, 
drugs acting as NSAIDs or anti-pyretics, such as ibuprofen, appear to be able to ameliorate these 
symptoms. Patients with SCN11A related small fibre neuropathy experience pain, tingling and 
numbness in their arms and legs. Patients may experience diarrhoea which is consistent with 
expression of Nav1.9 in the gut [131].  
Surprisingly, a few SCN11A gain of function mutations cause a complete insensitivity to pain 
[80,98,70]. Several possible explanations for how enhanced channel function leads to reduced 
neuronal excitability have been suggested [29], although arguments concerning modifications of 
channel gating kinetics as the primary cause seem incomplete and are based on voltage-clamp 
recordings whose  interpretation may not be straightforward. It is thought that increased 
activation/inactivation gating overlap (or window current) depolarise the Nav1.9 expressing neurons. 
This prolonged depolarisation causes rapidly gating Na+ channels (e.g. Nav1.7 and Nav1.8) to enter 
the inactivated state [65]. Since these channels underpin action potential generation and propagation, 
the depolarizing block of Nav1.7 and Nav1.8 in nerve endings leads to an overall decrease in 
excitability. It was noted that the mutations that lead to CIP are those that produced the largest shift in 
the activation threshold of the channel; whereas those that lead to familial episodic pain and painful 
small fibre neuropathy cause smaller shifts, table 6 [29]. Also of note, SCN11A CIP mutations are all 
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localised to transmembrane segment 6, figure 7. However, several issues are difficult to reconcile with 
the above explanation for the painless phenotype. Firstly, Nav1.9 is expressed in the IB4+ subset of 
neurons and not in all DRG neurons (at least in rodents). Therefore, a depolarising block in this 
subset of neurons alone is not expected to cause a complete loss of pain. Second, NaV1.8 which is 
expressed in most nociceptors (i.e. in same neurons as Nav1.9) is a channel known to operate at 
more depolarised membrane potentials and can maintain excitability, even in the face of a 
depolarised membrane potential [111,134,56,104]. 
Concluding remarks 
In the past 20 years mouse models and human genetics have confirmed that Nav1.7 and Nav1.9 play 
critical roles in pain signalling. The link between genotype and phenotype for mutations in both 
channels is poorly understood. Symptoms manifest in extremities (mainly in the feet/legs) in most 
human conditions. In Nav1.7 channel mutations, there is a link between mutations that cause 
enhancement of activation to PEM; and mutations that cause incomplete inactivation to PEPD. The 
physiological or microanatomical basis for these associations in terms of nerve ending function are 
only partly understood. In Nav1.9 channel mutations, a clear understanding of why most gain of 
function mutations cause painful conditions while those affecting segment 6 cause insensitivity to pain 
is also lacking, although insensitivity to pain is hypothesised to be caused by reduced excitability due 
to a depolarising block [121, 122]. 
Nonetheless, available evidence confirms a critical role for both channels in pain earning them a 
position in the list of potential drug targets. Ablation of Nav1.8 and Nav1.9 in mice does not lead to 
leathaility or any observable detrimental effects. Ablation of Nav1.7 in human [19] and in adult mice 
[107] does not lead to leathality. Reassuringly, there are no reported respiratopry or behvioural 
abnormalites as a reuslt of the absence of all three channels in mouse and human. Yet important 
challenges for VGSC blockers in chronic pain remain, developing subunit sepecific blockers being the 
first. This is important conidering that VGSC blcokers would need to be admisntraered regularly to 
treat chronic pain and perhaps at hgiher doses when pain is sever. Therefore VGSC blcokers would 
need to be safe for long term admisntration. The developement of specific and effective small 
molecule inhibitors of Nav1.7 is still elusive, despite efforts by several pharmaceutical companies 
[38,128,71]. The second challenge is the extent of Nav1.7 inhibition required for analgesia in vivo. 
Given that CIP carriers have normal pain phenotype, an Nav1.7 blocker may need to reduce channel 
activity to a level well below 50% to produce analgesia.  
The contribution of the endogenous opioid system to the phenotype of the SCN9A CIP mutation 
riases the question whether the CIP phenotype is a direct consequence of the loss of Nav1.7 [87,97]. 
Several papers provided compleing evidence that the loss of Nav1.7 reduces the excitability of DRG 
neurons per se. Deletion of Nav1.7 cuases an increase in action potential threshold in small-diameter 
DRG neurons [107]. Deletion of Nav1.7 causes a major decrease in DRG neurons responsiveness to 
the VGSC opener veratridine [89]. Mechanically-evoked spiking of C-fibers in the skin-nerve 
preparation were reduced  reduced in Nav1.7 KO mice[49]. No changes in the epxression of other 
VGSC channels were reported in the Nav1.7 KO mouse to contribute to the observed reduced 
excitability of DRG [107]. Furthermore, pain decificts in a rat model of Nav1.7 deletion were not 
reversed by opioid the receptor antagonist naloxone [14]. Therefore, while an increase in spinal cord 
opioid synthesis would reduce signal transmission at the first synpase in CIP paitients, the loss of 
Nav1.7 has a profund effect of the excitabilty of DRG neurons (i.e. signal initiations).  
lack of reported Nav1.9 loss of function mutations may indicate that its loss does not lead to a major 
phenotype in humans, raising doubts as to whether a blocker would lead to a major analegisc effect. 
Finally, considering that nociceptors express at least two of the peripheral VGSC subunits (Nav1.7, 
Nav1.8 and Nav1.9), an effective analegesic strategy may ultimately result from a combination of 
blockers against these subunits to have additive and synergistic effects on nociceptors. The 
effectiveness of various drug combinations to reduce neuronal excitability can only be measured on 
DRG neurons because they express the target VGSCs at biologically relevent levels. Equally 
important for the evlauation of any drugs combination is its effect on non-nociceptors as well as 
nociceptors. We recently decribed a relevant assay [88] and provided proof-of-concept data that 
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showed a combination of Nav1.7 and Nav1.8 blockers produced a reduction in excitability in nociceptor 
close to that measured in Nav1.7 KO [89]. Changing the consitituents and doses in VGSC blocker 
combinations may enable clinciaions to manage chronic pain in patients over long time periods. 
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Mutation Notes on effect Ref 
L858H  [127] 
I848T  [127,33] 
L858F  [33] 
N395K  [33] 
F216S  [33] 
P610T  [33] 
R1150W  [33] 
F1449V  [31] 
S241T  [86] 
A863P  [59] 
I136V Late onset + Reduced  intradermal fiber density [78] 
A1632E causes PEM and PEPD like symptoms [40] 
Q10R Late onset [55] 
V400M carbamazepine-responsive [46] 
L823R shifts fast-inactivation to more negative potentials, 
unusual in PEM 
[76] 
S211P  [39] 
I234T Sitting as well as heat trigger pain, One of the largest 
shift in activation voltage. 
[1] 
G616R  [17] 
Del-L955 Large hyperpolarised shift in activation voltage with a 
large shift in inactivation voltage in same direction 
leading to mild symptoms 
[15] 
I228M  [41] 
Q875E Severe pain [110] 
Q10K  [72] 
V1316A  [124,42] 
A1746G   [21] 
W1538R Described as W1550R in [26] [21] 
A1632T  [35] 
L245 V Incomplete fast inactivation but no shift in activation 
voltage 
[37] 
A1632G  [126] 
G856R PEM with impaired limb development [115] 
F826Y  [123] 
P187L  [132] 
N1245S  [54] 







Figure 1: Topological representation of SCN9A mutations that cause PEM. A VGSC -subunit 
consists of four homologous domains (DI-DIV). Each domain consists of six transmembrane 
segments. Three intracellular loops (L1-L2) connect the four domains. Note that most mutations are 
localised to domains I and II. Structures are not drawn to scale. 
 
 
Mutation Notes on effect Ref 
R996C  [45] 
V1298D  [45] 
V1298F  [45] 
V1299F  [45] 
I1461T  [45] 
F1462V  [45] 
T1464I  [45] 
M1627K  [45] 
A1632E Channel displays properties of PEM and PEPD [40] 
G1607R  [16] 
I228M Produces PEM like symptoms as well [41] 
R185H  [85] 
L1612P  [114] 
V1740L Patients suffer from headache [66] 





Figure 2: Topological representation of mutations that cause PEPD in the -subunit of NaV1.7. Note 
that most mutations are localised in L3 and domain III and IV. Structures are not drawn to scale. 
 
Mutation Notes on effect Ref 









Mutations have various impact on channel properties 
but all lead to hyperexcitability. 
[43] 
G856D 
Shifts activation voltage to more negative potentials. 





















Functional properties uncharacterised [36] 




Figure 3: Topological representation of SCN9A mutations that cause heritable SFN. Most mutations 
associated with SFN are found clustered around L1. Structures are not drawn to scale. 
 
Mutation Notes on effect Ref 
   
N641Y 
 
knockin mice exhibit significantly reduced thresholds 
to electrically induced seizures. 
[109] 
Q10R From patient with febrile seizures plus [13] 
G327E  [125] 
G327E 
From Twin patients with idiopathic focal epilepsy with 
Rolandic spikes 
[81] 
I775M From patient with febrile seizures [32] 
R429C From patient with febrile seizures plus [32] 
A442T 




From patient with genetic epilepsy with febrile seizures 
plus 
[130] 













































Figure 5: Topological representation of SCN9A mutations that cause CIP. Mutations associated with 






Figure 6. A) Upregulation of Nav1.9 in an Nav1.8 knock-out neuron, following the introduction of 500 
M GTP--S into the cell interior for 12 minutes. B) upregulation of Nav1.9 using intracellular GTP--S 
gives rise to changes in the firing properties of Nav1.8 knock-out neuron, with reductions in current 
and voltage -threshold, recorded from a holding potential of – 90 mV. The upregulated current gives 




Mutation Notes on effect Ref 
L811P 
CIP 





Increase current density 











I381T: Activation voltage shifted by -6.7 mV 













Episodic pain [93] 
R222H 
Episodic pain 
Activation voltage shifted by -6.4 mV 
[58] 
L1302F CIP [98] 
N1169S 
I1293V 
PEM like pain [132] 
L396P 
CIP 
Deactivation voltage shifted by -22.8 mV 
[70] 
L1302F CIP [65] 
N820Y Painful neuropathy [48] 
N816K Episodic pain [63] 
Table 6: SCN11A mutations that cause painful and painless human conditions. Mutations causing 
painless condition are associated with big shifts in either their activation or inactivation voltages.  
 
 
Figure 7: Topological representation of SCN11A mutations. Notice that all CIP causing mutations 
(red) are located in the transmembrane segment 6. 
